Ascletis Advances Two Novel Obesity Peptide Candidates with FDA IND Submissions

Ascletis has taken an important step forward in the development of next-generation obesity treatments by submitting two Investigational New Drug (IND) applications to the U.S. Food and Drug Administration. The filings mark the beginning of the regulatory pathway that could bring two promising peptide-based therapies closer to clinical testing in the United States.

The first candidate, ASC36, is a once-monthly injectable peptide that acts as an amylin receptor agonist. Amylin receptor agonists represent a growing area of interest in obesity research, as they work through pathways that can complement or extend the effects of other metabolic therapies. The convenience of a once-monthly dosing schedule, if supported by future trial data, could offer patients a more manageable treatment option compared to more frequent injection regimens.

The second application covers ASC36_35, a fixed-dose combination (FDC) that pairs ASC36 with a peptide GLP-1R/GIPR agonist, also formulated for once-monthly administration. Combination approaches that engage multiple metabolic receptor pathways have become a major focus in obesity drug development, with the goal of potentially improving efficacy while simplifying treatment regimens for patients managing weight-related health conditions.

The submission of these IND applications is a meaningful milestone, as it reflects the progress Ascletis has made in preclinical development and sets the stage for the company to seek clearance to begin human clinical trials in the U.S. If cleared, these programs would join a broader wave of innovation in the peptide therapeutics space, where researchers continue to explore new ways to help patients achieve sustainable, long-term weight management with less frequent dosing.

Once-monthly injectable options, if proven safe and effective through the clinical trial process, could represent a significant convenience improvement for patients who currently rely on weekly injections. As with all early-stage drug candidates, these therapies will need to progress through rigorous clinical evaluation before any conclusions about safety or effectiveness can be drawn. True North Labs will continue to follow this story as it develops.

This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR Agon – PR Newswire